ATA Guidelines Tools

Adults with Differentiated THyroid Cancer - 2025 Update

American Thyroid Association Quick-Reference GUIDELINES Apps

Issue link: https://eguideline.guidelinecentral.com/i/1540959

Contents of this Issue

Navigation

Page 4 of 49

5 ➤ Completeness of Surgical Resection: The goal of surgery is to remove safely as much thyroid cancer as possible. To define the completeness of resection, the AJCC created definitions that are used in these guidelines to facilitate communications. An R0 resection means that the surgical margin is microscopically negative for residual tumor. An R1 resection means that there is no residual macroscopic tumor, but that microscopically positive margins still demonstrate the presence of tumor. R2 resection means that gross (macroscopic) disease remains post-surgery. 131 I, RAI Administration ➤ Remnant ablation: RAI administration to destroy benign remnant thyroid tissue following total or near-total thyroidectomy. ➤ Adjuvant therapy: RAI administration to destroy suspected (but not identified) remaining thyroid cancer following total or near-total thyroidectomy. ➤ Therapeutic treatment: RAI administration to treat known residual or recurrent thyroid cancer, either initially or with subsequent progression of thyroid cancer after total or near-total thyroidectomy. ➤ Thyrotropin suppression therapy: Use of thyroid hormone to suppress serum thyrotropin (TSH) concentrations below the normal range based on the risk of recurrence and/or response to therapy.

Articles in this issue

Archives of this issue

view archives of ATA Guidelines Tools - Adults with Differentiated THyroid Cancer - 2025 Update